Login to Your Account

ThromboGenics and Alcon Get European Nod for Jetrea

By Cormac Sheridan
Staff Writer

Wednesday, January 23, 2013
ThromboGenics NV and its partner, the Alcon unit of Novartis AG, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Jetrea (ocriplasmin) as a treatment for vitreous macular traction, paving the way for a European launch in the second quarter.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription